SCHEMBL15933280

SCHEMBL15933280

CC(=O)c1cn(-c2cccc(Cl)c2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.47
KDM2B Q8NHM5 1/20 0.47
PHF8 Q9UPP1 1/20 0.47
KDM2A Q9Y2K7 1/20 0.47
IDO1 P14902 1/20 0.46
MLLT3 P42568 1/20 0.44
MLLT1 Q03111 1/20 0.44
PKM P14618 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
KDM4E B2RXH2 1/20 0.40
KDM1A O60341 1/20 0.40
FGFR1 P11362 1/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5509095 0.86 KDM4E (0.51) NOTUMKDM2BPHF8KDM2AIDO1
SCHEMBL30504030 0.86 KDM4E (0.51) NOTUMKDM2BPHF8KDM2AIDO1
SCHEMBL10414274 0.85 KDM2B (0.47) NOTUMKDM2BPHF8KDM2AIDO1
SCHEMBL12191234 0.85 MLLT3 (0.44) NOTUMMLLT3MLLT1KMT2AMEN1
SCHEMBL15930135 0.84 KDM2B (0.44) NOTUMKDM2BPHF8KDM2AIDO1
SCHEMBL24812338 0.82 KDM4E (0.45) NOTUMMLLT3MLLT1KMT2AMEN1
SCHEMBL9827113 0.82 ALDH1A1 (0.55) NOTUMKDM2BPHF8KDM2AIDO1
SCHEMBL9827529 0.81 KDM4E (0.50) NOTUMKDM2BPHF8KDM2AIDO1
SCHEMBL9827734 0.81 NOTUM (0.73) NOTUMKMT2AMEN1POLBSMN1; SMN2
SCHEMBL12191226 0.79 SMN1; SMN2 (0.51) PKMKMT2AMEN1KDM4EFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170158712-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-08 US disclosed
EP-2739628-B1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-07 EP disclosed
US-9611274-B2 Macrocycles as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-04-04 US disclosed
US-20160068544-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-03-10 US disclosed
US-9221818-B2 Macrocycles as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2015-12-29 US disclosed
US-20140221338-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068544-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F12 NOTUM 2506/4885KDM2B 896/4885PHF8 2253/4885
US-20140221338-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F12 NOTUM 2506/4885KDM2B 896/4885PHF8 2253/4885
US-20170158712-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F12 NOTUM 2506/4885KDM2B 896/4885PHF8 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.